The Peptide Wiki
Mapping Knowledge.
Advancing Discovery.
📩 Subscribe
// STATE LEGISLATION TRACKER

Pennsylvania HB 2431: An Act amending Title 35 (Health and Safety) of the Pennsylvania Consolidated Statutes, in public safety, providing for

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Failed
State
Pennsylvania
Bill
HB 2431
Filed
2018-05-23
Read the bill
OpenStates →
Last reviewed
2026-10-02

Plain-English Summary

Pennsylvania HB2431 would have required opioid treatment agreements before a first opioid prescription for chronic pain. It does not appear to target compounded peptides, off-label peptide prescribing, telehealth, naturopathic or NP scope, or FDA 503A/503B compounding.

Key Points

  • No direct impact on peptide access or compounded peptide prescribing
  • Applies to controlled substances containing opioids for chronic pain
  • Would add consent, counseling, and treatment agreement paperwork
  • Does not change telehealth, NP, naturopathic, or compounding rules
  • Relevant only if a peptide patient also receives chronic opioid therapy

What to Watch For

i
Note This is an opioid prescribing bill, not a peptide or compounding bill.
!
Concern Clinicians prescribing chronic opioids would face added documentation and agreement requirements.
i
Note No apparent change to FDA 503A/503B compounding, off-label prescribing, or peptide prescribing.

Where the Bill Stands

HB2431 was referred to the Pennsylvania House Health Committee on May 23, 2018 and did not advance before the 2017-2018 session ended.
· Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.
Bill page generated 2026-11-04 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws